Amblyopia, the most common cause of monocular visual impairment in children, affects 2-3% of the general population. Traditionally, amblyopia is treated using an adhesive eye patch to cover the fellow eye. However, child compliance is low for this form of treatment because the patch is uncomfortable and creates a social stigma for the child. The purpose of this study is to test the efficacy of a more child-friendly novel intermitten occlusion therapy (IO Therapy) glasses.
Our Specific Aims : (1) To assess the efficacy of IO Therapy for severe amblyopia; (2) To characterize objective compliance of IO Therapy with a high-tech microsensor. This proposal is the first study to determine the clinical effectiveness of IO Therapy as a novel therapeutic approach for treating severe amblyopia. The findings from this proposal will lead to: 1) a more child-friendly and customizable form of amblyopia treatment; 2) a characterization of individual objective compliance, enabling us to develop a patient- centered strategy of IO Therapy. This new direction is consistent with President Obama`s Precision Medicine Initiative in 2015.
These exploratory studies relate to public health through two means. First, they may add intermittent occlusion as an alternative, child-friendly amblyopia treatment. Secondly, they characterize objective compliance with intermittent occlusion therapy. The proposed research will likely lead to a paradigm shift where customizable intermittent occlusion glasses for amblyopia treatment replaces the conventional 'one-size-fit-all' patching occlusion, thereby significantly improving the vision and treatment experience of the pediatric population.
|Wang, Jingyun; Neely, Daniel E; Galli, Jay et al. (2016) A pilot randomized clinical trial of intermittent occlusion therapy liquid crystal glasses versus traditional patching for treatment of moderate unilateral amblyopia. J AAPOS 20:326-31|